spacer
home > ict > winter 2019 > improving outcomes in diabetes research
PUBLICATIONS
International Clinical Trials

Improving Outcomes in Diabetes Research

Diabetes is often referred to as an epidemic, with an estimated 415 million adults worldwide living with the condition, according to the International Diabetes Federation Diabetes Atlas – approximately 1 in 11 of the adult population (1). What’s more, this figure is expected to rise to 642 million people worldwide by 2040. With a reported 46% of people with diabetes undiagnosed, these figures are, realistically, much higher.

With so much of the population suffering, pharmaceutical companies are continuing to invest in research into this condition in a bid to bring new and improved treatments to market across the globe. With this in mind, this article will discuss the current status of diabetes clinical research. In particular, it will provide an overview of the current diabetes landscape, including the types of disease and condition management, as well as the challenges of clinical research. Putting the person with diabetes at the heart of the development process will demonstrate how sponsors can implement patient-centric electronic data capture solutions which improve the user experience and support better study outcomes.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Katie Garner is the Therapeutic Areas Advisor at CRF Bracket. She is responsible for providing specific therapeutic advice and supporting the therapeutic, sales, marketing, and product development teams. Previously, Katie worked as a Project Manager for a health outcomes consultancy and at the NHS Purchasing and Supply Agencies Centre for Evidence-Based Purchasing. She has also worked for the Medicine and Healthcare products Regulatory Agency as a Senior Medical Device Specialist, responsible for the safety and regulation of in vitro diagnostic and contraceptive medical devices.
spacer
Katie Garner
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

AstroNova introduces its range of grass paper labels derived from grass for high quality organic products

Dietzenbach, 29 April 2019, AstroNova GmbH, European headquarters of AstroNova Inc. (RI, USA), responsible for Sales and Customer Service in Europe, the Middle East and Africa (EMEA), is extending its Product Identification range with new approved labelling for direct foodstuff contact.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: 1st Quarter 2014

Synergy Research Group

In summary, Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement